Paroxysmal Nocturnal Hemoglobinuria research hub

Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis

This study looks at a new add-on medicine, danicopan, for young people (12-17 years old) with a rare blood condition called PNH. It aims to see if danicopan can improve red blood cell levels when added to their current treatment.